Cargando…

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease

Detalles Bibliográficos
Autores principales:	Uehara, Tatsuki, Wakui, Hiromichi, Tamura, Kouichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982785/ https://www.ncbi.nlm.nih.gov/pubmed/36869146 http://dx.doi.org/10.1038/s41440-023-01241-x

Ejemplares similares

Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension
por: Azushima, Kengo, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
por: Yu, Cheng-Wei, et al.
Publicado: (2023)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease
por: Sukahri, Samshol, et al.
Publicado: (2021)

Causes of erectile dysfunction in non-alcoholic fatty liver disease
por: Tarik Kani, Haluk, et al.
Publicado: (2021)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
por: Tsukamoto, Shunichiro, et al.
Publicado: (2023)

In the quest for treating alcohol liver disease
por: Ciocan, Dragos, et al.
Publicado: (2022)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Non-alcoholic fatty liver disease may be associated with endothelial dysfunction
por: Balta, Sevket, et al.
Publicado: (2014)

Endothelial dysfunction and carotid atherosclerosis in non-alcoholic fatty liver disease
por: Dogru, Teoman, et al.
Publicado: (2014)

“Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Study of Endothelial Dysfunction in Patients With Non-alcoholic Fatty Liver Disease
por: Jose, Nijin, et al.
Publicado: (2021)

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease
por: Mazzini, Guilherme S., et al.
Publicado: (2018)

Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis
por: Kotani, Kazuhiko, et al.
Publicado: (2021)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
por: Virk, Ghazala S, et al.
Publicado: (2023)

Low–Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Zuarth-Vázquez, Julia, et al.
Publicado: (2023)

Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Wu, Dongqing, et al.
Publicado: (2021)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
por: Yoon, Eileen Laurel, et al.
Publicado: (2023)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Jambulingam, Nila, et al.
Publicado: (2023)

Multimodal assessment of non-alcoholic fatty liver disease with transmission-reflection optoacoustic ultrasound
por: Lafci, Berkan, et al.
Publicado: (2023)

From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease
por: Di Sessa, Anna, et al.
Publicado: (2017)

The ultrasound‐guided attenuation parameter is useful in quantification of hepatic steatosis in non‐alcoholic fatty liver disease
por: Ogino, Yu, et al.
Publicado: (2021)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

The Clinical Significance of Serum Ferritin in Pediatric Non-Alcoholic Fatty Liver Disease
por: Na, Ji Hoon, et al.
Publicado: (2014)

Correction to: “Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dnp14t0qhbrbdipv9vhad60pbh